


| | | | | | |
|---|-----------------|----------|--------------|--------------------------------|------------------|
| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | | | | Docket No. RLL-313US | |
| In Re Application Of: MEHTA, et al. | | | | | |
| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
| 10/552,322 | October 7, 2005 | TBA | 26815 | TBA | 2737 |
| Title: OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | | | | | |
| Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 | | | | | |
| 37 CFR 1.97(b) | | | | | |
| 1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. | | | | | |
| 37 CFR 1.97(c) | | | | | |
| 2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: | | | | | |
| <div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div> | | | | | |
| OR | | | | | |
| <div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div> | | | | | |

P10A/REV06

| | | | | | | |
|--|-----------------|----------|--------------|----------------|--------------------------------|--|
| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | | | | | Docket No. RLL-313US | |
| In Re Application of: MEHTA, et al. | | | | | | |
| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. | |
| 10/552,322 | October 7, 2005 | TBA | 26815 | TBA | 2737 | |
| Title: OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | | | | | | |
| <div style="text-align: center;"> Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) </div> <p> <input type="checkbox"/> A check in the amount of _____ is attached. </p> <p> <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>50-0912</u> as described below. </p> <div style="margin-left: 40px;"> <input checked="" type="checkbox"/> Charge the amount of _____ </div> <div style="margin-left: 40px;"> <input checked="" type="checkbox"/> Credit any overpayment. </div> <div style="margin-left: 40px;"> <input checked="" type="checkbox"/> Charge any additional fee required. </div> <p> <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. </p> <p> WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. </p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Transmission by Facsimile*</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ (Date)</div> </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ Signature</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: center;">_____ Typed or Printed Name of Person Signing Certificate</div> </div> </div> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Mailing by First Class Mail</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ (Date)</div> </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">_____ Signature of Person Mailing Correspondence</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: center;">_____ Typed or Printed Name of Person Mailing Certificate</div> </div> </div> </div> <p> *This certificate may only be used if paying by deposit account. </p> <div style="display: flex; justify-content: space-between; align-items: flex-end; margin-top: 20px;"> <div style="width: 45%;"> <div style="text-align: center;">_____ Signature</div> <p>George E. Heibel, Esq. Reg. No. 42,648</p> <p>Customer No. 26815</p> </div> <div style="width: 45%;"> <p>Dated: January 19, 2007</p> </div> </div> | | | | | | |
| cc: | | | | | | |

P10A/REV06

INFORMATION DISCLOSURE CITATION



Docket No.: RLL-313US Serial No.: 10/552,322

Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group:

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|----|-----------------|------------|--------------------------|-------|----------|-------------------------------|
| | A1 | 4,801,600 | 1/31/1989 | Wang <i>et al.</i> | 514 | 376 | |
| | A2 | 4,921,869 | 5/1/1990 | Wang <i>et al.</i> | 514 | 376 | |
| | A3 | 5,254,577 | 10/19/1993 | Carlson <i>et al.</i> | 514 | 376 | |
| | A4 | 5,547,950 | 8/20/1996 | Hutchinson <i>et al.</i> | 514 | 252 | |
| | A5 | 5,700,799 | 12/23/1997 | Hutchinson <i>et al.</i> | 514 | 235.8 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO | |
|--|-----|-----------------|------------|---------|-------|----------|-------------------------|--|
| | B1 | EP 0 312 000 | 4/19/1989 | EPO | C07D | 263/20 | | |
| | B2 | EP 0 352 781 | 1/31/1990 | EPO | C07D | 263/20 | | |
| | B3 | JP 11-322729 | 11/24/1999 | Japan | C07D | 263/20 | | |
| | B4 | WO 90/02744 | 3/22/1990 | PCT | C07D | 413/04 | | |
| | B5 | WO 93/09103 | 5/13/1993 | PCT | C07D | 263/20 | | |
| | B6 | WO 93/23384 | 11/25/1993 | PCT | C07D | 263/20 | | |
| | B7 | WO 99/64417 | 12/16/1999 | PCT | C07D | 413/14 | | |
| | B8 | WO 00/21960 | 4/20/2000 | PCT | C07D | 413/14 | | |
| | B9 | WO 02/06278 | 1/24/2002 | PCT | C07D | 413/14 | | |
| | B10 | WO 02/51819 | 7/4/2002 | PCT | C07D | 263/24 | | |
| | B11 | WO 03/07870 | 1/30/2003 | PCT | A61K | | | |
| | B12 | WO 03/27083 | 4/3/2003 | PCT | C07D | 263/24 | | |


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|--|
| C1 | Antibacterial & Antifungal Drug Discovery & Development Summit, Strategic Research Institute, June 28-29, 2001, Amsterdam, The Netherlands |
| C2 | Pae <i>et al.</i> , "Synthesis and <i>In Vitro</i> Activity of New Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles", <i>Bioorganic & Medicinal Chemistry Letters</i> , 9(18):2679-2684 (1999) |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---------------------------------|------------------------|
| INFORMATION DISCLOSURE CITATION  | Docket No.: RLL-313US | Serial No.: 10/552,322 |
| | Applicants: MEHTA <i>et al.</i> | |
| | Filed: 10/7/2005 | Group: |

| | | |
|--|-----|--|
| | | Park and Britteli et al, "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Derivatives". <i>Journal of Medicinal Chemistry</i> , <u>35</u> (6):1156-1165 (1992) |
| | C4 | Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 1. Conversion of 5-Substituent on Oxazolidinone", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):347-352 (2001) |
| | C5 | Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. ¹⁾ Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):353-360 (2001) |
| | C6 | Tokuyama et al, "Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 3. ¹⁾ Synthesis and Evaluation of 5-Thiocarbamate Oxazolidinones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>49</u> (4):361-367 (2001) |
| | C7 | Yu and Huiyuan, "Synthesis and Antibacterial Activity of Linezolid Analogues," <i>Bioorganic & Medicinal Chemistry Letters</i> , <u>12</u> (6):857-859 (2002) |
| | C8 | Gordeev, "Combinational lead discovery and optimization of antimicrobial oxazolidinones", <i>Current Opinion in Drug Discovery & Development</i> , <u>4</u> (4):450-461 (2001) |
| | C9 | Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", <i>Journal of Medicinal Chemistry</i> , <u>32</u> (8):1673-1681 (1989) |
| | C10 | Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 2. The "A" Group", <i>Journal of Medicinal Chemistry</i> , <u>33</u> (9):2569-2578 (1990) |
| | C11 | Posters No. 1822-1834, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada |
| | C12 | Posters No. 1023, 1040-1051, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25, 2001, Chicago, USA |
| | C13 | Wang et al., "Chiral Synthesis of DUP 721, a New Antibacterial Agent ¹ ", <i>Tetrahedron</i> , <u>45</u> (5):1323-1326 (1989) |
| | | |

| | |
|--|-----------------|
| EXAMINER | DATE CONSIDERED |
| <small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small> | |